Antihepatic Fibrosis Drugs in Clinical Trials
© 2020 Authors..
Liver fibrosis is not an independent disease. It refers to the abnormal proliferation of connective tissues in the liver caused by various pathogenic factors. Thus far, liver fibrosis has been considered to be associated with a set of factors, such as viral infection, alcohol abuse, non-alcoholic fatty liver disease, and autoimmune hepatitis, as well as genetic diseases. To date, clinical therapeutics for liver fibrosis still face challenges, as elimination of potential causes and conventional antifibrotic drugs cannot alleviate fibrosis in most patients. Recently, potential therapeutic targets of liver fibrosis, such as metabolism, inflammation, cell death and the extracellular matrix, have been explored through basic and clinical research. Therefore, it is extremely urgent to review the antihepatic fibrosis therapeutics for treatment of liver fibrosis in current clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of clinical and translational hepatology - 8(2020), 3 vom: 28. Sept., Seite 304-312 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guo, Yue-Cheng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cholestatic liver diseases |
|---|
| Anmerkungen: |
Date Revised 22.10.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.14218/JCTH.2020.00023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316524905 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316524905 | ||
| 003 | DE-627 | ||
| 005 | 20231225161257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14218/JCTH.2020.00023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316524905 | ||
| 035 | |a (NLM)33083254 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guo, Yue-Cheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antihepatic Fibrosis Drugs in Clinical Trials |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.10.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 Authors. | ||
| 520 | |a Liver fibrosis is not an independent disease. It refers to the abnormal proliferation of connective tissues in the liver caused by various pathogenic factors. Thus far, liver fibrosis has been considered to be associated with a set of factors, such as viral infection, alcohol abuse, non-alcoholic fatty liver disease, and autoimmune hepatitis, as well as genetic diseases. To date, clinical therapeutics for liver fibrosis still face challenges, as elimination of potential causes and conventional antifibrotic drugs cannot alleviate fibrosis in most patients. Recently, potential therapeutic targets of liver fibrosis, such as metabolism, inflammation, cell death and the extracellular matrix, have been explored through basic and clinical research. Therefore, it is extremely urgent to review the antihepatic fibrosis therapeutics for treatment of liver fibrosis in current clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cholestatic liver diseases | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Liver fibrosis | |
| 650 | 4 | |a Non-alcoholic steatohepatitis | |
| 650 | 4 | |a Therapeutics | |
| 700 | 1 | |a Lu, Lun-Gen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical and translational hepatology |d 2013 |g 8(2020), 3 vom: 28. Sept., Seite 304-312 |w (DE-627)NLM252610520 |x 2310-8819 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g number:3 |g day:28 |g month:09 |g pages:304-312 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14218/JCTH.2020.00023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |e 3 |b 28 |c 09 |h 304-312 | ||